title: The oncolytic herpes simplex virus vector G47∆ effectively targets breast             cancer stem cells.
abstract: Accumulating evidence suggests that breast cancer originates from cancer             stem cells (CSCs), which comprise a small percentage of the overall tumor but             are highly tumorigenic and pluripotent with unlimited proliferation potential.             Furthermore, CSCs are highly resistant to conventional treatment, which may explain             certain difficulties in treating cancer with current therapy options. In this             study, the third generation oncolytic herpes simplex virus (oHSV) vector G47∆             effectively killed different subtypes of breast cancer cells, with more than 98%             of the tumor cells killed by Day 5. Moreover, G47∆ targeted equally non-cancer             stem cells (NCSCs) and CSCs which showed resistance to paclitaxel. We demonstrated             that G47∆ effectively replicated and spread among CSCs. G47∆ also impaired the             self-renewal ability of CSCs, as the viable cells were unable to form secondary             tumor spheres. We also showed that G47∆ was able to induce the regression of tumor             xenografts in BALB/c nude mice and demonstrated the ability of G47∆ to synergize             with paclitaxel by killing both NCSCs and CSCs, suggesting that oHSV may be an             effective treatment modality for patients with breast cancer.
authors.affiliation: Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, PR China.
authors.forename: Weigen
authors.initials: W
authors.lastname: Zeng
authors.forename: Pan
authors.initials: P
authors.lastname: Hu
authors.forename: Juekun
authors.initials: J
authors.lastname: Wu
authors.forename: Jiani
authors.initials: J
authors.lastname: Wang
authors.forename: Junjie
authors.initials: J
authors.lastname: Li
authors.forename: Lan
authors.initials: L
authors.lastname: Lei
authors.forename: Renbin
authors.initials: R
authors.lastname: Liu
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D001943:Breast Neoplasms / Q000628:therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D014411:Neoplastic Stem Cells / Q000502:physiology* / Q000821:virology; D050504:Oncolytic Viruses / Q000502:physiology*; D017239:Paclitaxel / Q000494:pharmacology*; D018139:Simplexvirus / Q000502:physiology*; D018874:Spheroids, Cellular / Q000502:physiology / Q000821:virology; D023041:Xenograft Model Antitumor Assays
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel